Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Stock Report

Market Cap: US$1.1b

Syndax Pharmaceuticals Management

Management criteria checks 3/4

Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 3.67 years. total yearly compensation is $7.71M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $511.09K. The average tenure of the management team and the board of directors is 3.3 years and 9.3 years respectively.

Key information

Michael Metzger

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage9.28%
CEO tenure3.7yrs
CEO ownership0.04%
Management average tenure3.3yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

Syndax Expands Revuforj Approval, Buy

Oct 27

Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Aug 06
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking

Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Aug 05
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results

Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?

Apr 26
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?
User avatar

FDA Approvals Will Expand AML And cGVHD Treatment Options

Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology.

Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?

Feb 07
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?

Syndax Looks Tantalizing, But Looks Can Be Deceptive

Jan 22

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Michael Metzger's remuneration changed compared to Syndax Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$335m

Mar 31 2025n/an/a

-US$331m

Dec 31 2024US$8mUS$715k

-US$319m

Sep 30 2024n/an/a

-US$297m

Jun 30 2024n/an/a

-US$264m

Mar 31 2024n/an/a

-US$241m

Dec 31 2023US$9mUS$678k

-US$209m

Sep 30 2023n/an/a

-US$176m

Jun 30 2023n/an/a

-US$160m

Mar 31 2023n/an/a

-US$153m

Dec 31 2022US$4mUS$640k

-US$149m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

US$818k

Mar 31 2022n/an/a

US$15m

Dec 31 2021US$3mUS$594k

US$25m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$2mUS$577k

-US$77m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$3mUS$540k

-US$56m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$65m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$2mUS$506k

-US$74m

Compensation vs Market: Michael's total compensation ($USD7.71M) is above average for companies of similar size in the US market ($USD3.47M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Metzger (54 yo)

3.7yrs
Tenure
US$7,707,176
Compensation

Mr. Michael A. Metzger is an Independent Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a memb...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Metzger
CEO & Director3.7yrsUS$7.71m0.045%
$ 511.1k
Keith Goldan
CFO, Treasurer & Chief Accounting Officer3.3yrsUS$2.82m0.019%
$ 221.4k
Luke Albrecht
Senior VP9.2yrsUS$2.47m0.098%
$ 1.1m
Steven Closter
Chief Commercial Officer1.6yrsUS$3.66m0.082%
$ 937.3k
Peter Ordentlich
Co-Founder & Chief Scientific Officer20yrsno datano data
Richard Heyman
Co-Founderno datano datano data
Ronald Evans
Co-Founderno datano datano data
Michael Downes
Co-Founderno datano datano data
Sharon Klahre
Vice President of Investor Relations & Communications3.3yrsno datano data
Kevin McManus
Chief People Officer2.4yrsno datano data
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer2.8yrsno datano data
Anjali Ganguli
Chief Business Officer4.1yrsUS$2.07mno data
3.3yrs
Average Tenure
56yo
Average Age

Experienced Management: SNDX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Metzger
CEO & Director6.3yrsUS$7.71m0.045%
$ 511.1k
Ronald Evans
Co-Founder9.3yrsno datano data
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer9.3yrsno datano data
Keith Katkin
Independent Director8.6yrsUS$507.19k0.087%
$ 991.5k
Pierre Legault
Independent Director8.8yrsUS$501.49k0.075%
$ 859.3k
Dennis Podlesak
Independent Chairman16.8yrsUS$954.42k0.017%
$ 190.7k
George Sledge
Member of Scientific Advisory Board8.5yrsUS$23.05kno data
Jedd D. Wolchok
Member of Scientific Advisory Board9.3yrsno datano data
Hope Rugo
Member of Scientific Advisory Board9.3yrsno datano data
Samir Khleif
Member of Scientific Advisory Board9.3yrsno datano data
Julie Brahmer
Member of Scientific Advisory Board9.8yrsno datano data
Lisa Coussens
Member of Scientific Advisory Board8.8yrsno datano data
9.3yrs
Average Tenure
65yo
Average Age

Experienced Board: SNDX's board of directors are considered experienced (9.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/30 16:39
End of Day Share Price 2025/10/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syndax Pharmaceuticals, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Jason ZemanskyBofA Global Research
Madhu KumarB. Riley Securities, Inc.